ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of “Buy” from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has received a consensus rating of “Buy” from the eight ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $77.71.

Several equities analysts have weighed in on ANIP shares. Piper Sandler initiated coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price on the stock. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective for the company. Truist Financial increased their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, November 11th.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the transaction, the chief financial officer now owns 154,468 shares of the company’s stock, valued at $8,617,769.72. This represents a 4.63 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the sale, the senior vice president now owns 49,059 shares in the company, valued at $2,943,540. This trade represents a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 42,381 shares of company stock worth $2,441,556. Corporate insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Thrivent Financial for Lutherans grew its holdings in shares of ANI Pharmaceuticals by 2.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock valued at $777,000 after acquiring an additional 299 shares in the last quarter. Louisiana State Employees Retirement System grew its stake in ANI Pharmaceuticals by 3.9% in the third quarter. Louisiana State Employees Retirement System now owns 8,000 shares of the specialty pharmaceutical company’s stock valued at $477,000 after purchasing an additional 300 shares in the last quarter. Exchange Traded Concepts LLC increased its position in shares of ANI Pharmaceuticals by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock worth $684,000 after purchasing an additional 310 shares during the last quarter. New York State Teachers Retirement System raised its stake in shares of ANI Pharmaceuticals by 1.7% during the 3rd quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock worth $1,439,000 after purchasing an additional 394 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of ANI Pharmaceuticals by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock valued at $246,000 after buying an additional 412 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP opened at $60.42 on Tuesday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a 1-year low of $52.50 and a 1-year high of $70.81. The stock has a market capitalization of $1.27 billion, a P/E ratio of -109.85 and a beta of 0.73. The business has a 50-day moving average price of $56.35 and a two-hundred day moving average price of $58.66.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.25. The business had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals’s revenue was up 12.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.05 earnings per share. Equities analysts predict that ANI Pharmaceuticals will post 3.86 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.